Atara Biotherapeutics

Traded on the St. Petersburg Stock Exchange
Atara Biotherapeutics is a leading allogeneic T-cell immunotherapy company pioneering the development therapies for patients with serious diseases including tumors, cancers and autoimmune diseases.
Atara Biotherapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Atara Biotherapeutics balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Atara Biotherapeutics cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Atara Biotherapeutics multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Atara Biotherapeutics profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Atara Biotherapeutics assets
Atara Biotherapeutics cash flows

Atara Biotherapeutics shares

TickerNameTypeNominal valueISINPrice
ATRA:USAtara Biotherapeutics, Inc.Common share-US0465131078$0.6974
Atara Biotherapeutics news
06.05.2022
Atara Biotherapeutics' GAAP loss for 3 months of 2022 was $88.105 million, up 12.5% from $78.335 million in the previous year. Revenue increased 2.1 times to $7.314 million from $3.552 million a year earlier.
Source: {source} pictogram investors.atarabio.com
Pictogram next
01.03.2022
Atara Biotherapeutics reported a GAAP loss of $340.141 million for 2021, up 10.9% from $306.62 million in the previous year. Revenue was $20.34 million; the company did not generate revenue a year earlier.
Source: {source} pictogram investors.atarabio.com
Pictogram next
04.11.2021
Atara Biotherapeutics' GAAP loss for 9M 2021 was $246.792 million, up 9.5% from $225.313 million in the prior year. Revenue was $12.792 million versus $0 million. The company did not generate revenue a year earlier.
Source: {source} pictogram investors.atarabio.com
Pictogram next
09.08.2021
Atara Biotherapeutics' GAAP loss for 6M 2021 was $162.128 million, up 7.4% from $150.965 million in the prior year. Revenues were $7,422 million. The company did not generate revenues a year earlier.
Source: {source} pictogram investors.atarabio.com
Pictogram next
All Atara Biotherapeutics news
General information
Company nameAtara Biotherapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Mailing address611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Websitewww.atarabio.com
Information disclosurewww.sec.gov